Case Study: DS-8201a is an antibody-drug conjugate (ADC) approved by the US FDA for a certain population diagnosed with HER2-positive solid tumors. Using only 1 mg of DS-8201a, our DMPK team successfully completed a 28-day in vivo mouse PK study recently. Through meticulous planning, precise sample handling, and the use of highly automated workstations, our team achieved results that were consistent with the literature, demonstrating both efficiency and scientific rigor.
28-days intravenous (IV) inoculation and sample collection by serial bleeding of BALB/c nude mice with only 1 mg of ADC
Bioanalysis ligand-binding/ELISA assays of whole blood samples using automated GyroLab® xPlore™ workstation
Complete quantification of DS-8201a and its pharmacokinetic (PK) properties
Download the case study to learn details:
